Novartis Pharma AG: Novartis Cosentyx receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis

New approvals are based on JUNIPERA trial data showing Cosentyx (secukinumab) demonstrated reduced flare risk versus placebo and improvement in disease activity observed over two years across both enthesitis-related

Related Keywords

United States , Cincinnati , Ohio , America , American , Hermine Brunner , Pabout Cosentyx , Isabella Zinck , Michael Meo , Thomas Hungerbuehler , Dermatol Venereol , Louise Clark , Samir Shah , Parag Mahanti , Julie Masow , Todd Fox , Sloan Simpson , Alina Levchuk , Global Head Of Medical Affairs Immunology , Twitter , Ministry Of Health , American College Of Rheumatology , Novartis , Novartis Europharm , American Academy Of Dermatology , Virtual Congress , Drug Administration , Rheumatology Research Alliance Registry , Novartis Us External Communications , European Alliance Of Associations , International League , Exchange Commission , Novartis Pharma Communications , Novartis Pharmaceuticals Corp , Cincinnati Children , Global Head , Medical Affairs Immunology , East Hanover , Enthesitis Related Arthritis , Juvenile Psoriatic Arthritis , Primary Results , Treatment Withdrawal , European Alliance , Associations For Rheumatology , Juvenile Arthritis , Childhood Arthritis , Rheumatology Research Alliance , Treatment In Children And Adolescents , Efficacy And Safety Results From , American College , American Academy , Virtual Meeting Experience , Provides Sustained Improvements , Psoriatic Arthritis , Pooled Safety , Dharma , Cosentyx , Eceives , Approval , Treatment , Children , Adolescents , Enthesitis , Elated , Arthritis , Psoriatic ,